Pro­tein ther­a­peu­tics biotech us­ing 'pro­tein bar­codes' in drug de­vel­op­ment se­cures new fi­nanc­ing — led by Jeff Hu­ber

3 years ago
Financing
Startups

#BIO22: Fire­side chat with Zachary Bren­nan and Ian Thomp­son

3 years ago

No­var­tis’ $650M cash bet on a near-term FDA OK for BeiGene’s Chi­na PD-1? It just got de­layed in­def­i­nite­ly

3 years ago
China
Pharma

No­vo Nordisk nabs pri­or­i­ty re­view vouch­er for $110M from Mar­i­nus as the biotech preps first drug launch

3 years ago
Financing
Deals

mR­NA al­ter­na­tive: No­vavax fi­nal­ly scores EUA for pri­ma­ry Covid-19 vac­cine se­ries

3 years ago
FDA+
Coronavirus

Reel­ing from PhII flop, Cy­tomX lays off 40% as ex­ecs go back to draw­ing board, seek new deals

3 years ago
People

In post-Roe guid­ance, HHS tells 60,000 phar­ma­cies: Don't stop dis­pens­ing abor­tion drugs

3 years ago
Pharma
Law

Amid glob­al ex­pan­sion, Sam­sung Bi­o­log­ics pledges emis­sions drops in new ESG re­port

3 years ago
Pharma
Manufacturing

Sanofi CEO Paul Hud­son of­floads two port­fo­lios to Ger­man phar­ma com­pa­ny in con­tin­ued ef­fort to prune prod­ucts

3 years ago
Deals
Pharma

Vivus’ Qsymia beats out weight loss com­peti­tors in pric­ing watch­dog's lat­est cost-ef­fec­tive­ness analy­sis

3 years ago
Pharma

FDA again spells out safe­ty con­cerns with oral type 1 di­a­betes drug while deny­ing Lex­i­con's at­tempt to over­turn a CRL

3 years ago
FDA+

Al­ny­lam sues Mod­er­na and Pfiz­er again over Covid-19 vac­cine patent in­fringe­ment

3 years ago
Pharma
Law

Te­va and Al­ler­gan reach an­oth­er opi­oid set­tle­ment, this time for $54M with San Fran­cis­co

3 years ago
Pharma
Law

FDA com­mis­sion­er's vi­sion: Time to re­vamp the ev­i­dence gen­er­a­tion sys­tem

3 years ago
FDA+

En­do con­sid­ers bank­rupt­cy fil­ing as it feels the heat from thou­sands of opi­oid law­suits — re­port

3 years ago
Pharma
Law

Mubadala Cap­i­tal-backed on­col­o­gy biotech adds more cash to Se­ries A; Opti­nose shares pooled da­ta on nasal spray

3 years ago
News Briefing

Covid-19 roundup: FDA re­port­ed­ly set to au­tho­rize No­vavax jab; As­traZeneca says its shot just as ef­fec­tive as mR­NA

3 years ago
Coronavirus

With failed NIH Covid-19 study, Hu­mani­gen CEO points to com­peti­tors' flops be­fore FDA nods

3 years ago
R&D
Coronavirus

Ama­zon joins Fred Hutch on clin­i­cal tri­al for per­son­al­ized can­cer vac­cine — re­port

3 years ago
R&D

Ther­a­peu­tic­sMD shares crater as an­tic­i­pat­ed M&A deal falls through

3 years ago
Deals

With eyes on Keytru­da patent cliff, Mer­ck takes a $290M swing at prostate can­cer

3 years ago
Deals
R&D

Fa­heem Has­nain forges a $120M pri­vate place­ment. So what did we learn from that?

3 years ago
Deals
Bioregnum

Cur­tain-rais­er da­ta keep an­a­lysts on edge ahead of Am­gen’s big Lumakras/PD-1 com­bo read­out

3 years ago
R&D

Pfiz­er dips its toe in­to fi­bro­sis and or­gan re­gen­er­a­tion, lead­ing raise ex­ten­sion for Bel­gium's Agomab

3 years ago
Financing
Startups
First page Previous page 494495496497498499500 Next page Last page
A service from the Financial Times